386 related articles for article (PubMed ID: 21952285)
1. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?
Slingluff CL
Cancer J; 2011; 17(5):343-50. PubMed ID: 21952285
[TBL] [Abstract][Full Text] [Related]
2. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
4. IRX-2 increases the T cell-specific immune response to protein/peptide vaccines.
Naylor PH; Hernandez KE; Nixon AE; Brandwein HJ; Haas GP; Wang CY; Hadden JW
Vaccine; 2010 Oct; 28(43):7054-62. PubMed ID: 20708999
[TBL] [Abstract][Full Text] [Related]
5. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
6. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Hibbitts S; Murphy C; Johansen N; Grosh WW; Yamshchikov GV; Neese PY; Patterson JW; Fink R; Rehm PK
Clin Cancer Res; 2007 Nov; 13(21):6386-95. PubMed ID: 17975151
[TBL] [Abstract][Full Text] [Related]
7. Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.
Harao M; Mittendorf EA; Radvanyi LG
BioDrugs; 2015 Feb; 29(1):15-30. PubMed ID: 25523015
[TBL] [Abstract][Full Text] [Related]
8. TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice.
Tanaka Y; Wada H; Goto R; Osada T; Yamamura K; Fukaya S; Shimizu A; Okubo M; Minamiguchi K; Ikizawa K; Sasaki E; Utsugi T
Sci Rep; 2020 Oct; 10(1):17284. PubMed ID: 33057061
[TBL] [Abstract][Full Text] [Related]
9. Rational Design of Antigen Incorporation Into Subunit Vaccine Biomaterials Can Enhance Antigen-Specific Immune Responses.
Tsoras AN; Wong KM; Paravastu AK; Champion JA
Front Immunol; 2020; 11():1547. PubMed ID: 32849524
[TBL] [Abstract][Full Text] [Related]
10. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
[TBL] [Abstract][Full Text] [Related]
11. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
12. A novel multi-epitope peptide vaccine against cancer: an in silico approach.
Nezafat N; Ghasemi Y; Javadi G; Khoshnoud MJ; Omidinia E
J Theor Biol; 2014 May; 349():121-34. PubMed ID: 24512916
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8
Zahm CD; Colluru VT; McNeel DG
Cancer Immunol Res; 2017 Aug; 5(8):630-641. PubMed ID: 28634215
[TBL] [Abstract][Full Text] [Related]
14. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells.
Assudani D; Cho HI; DeVito N; Bradley N; Celis E
Cancer Res; 2008 Dec; 68(23):9892-9. PubMed ID: 19047170
[TBL] [Abstract][Full Text] [Related]
15. Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies.
Klausen U; Holmberg S; Holmström MO; Jørgensen NGD; Grauslund JH; Svane IM; Andersen MH
Front Immunol; 2018; 9():2264. PubMed ID: 30327655
[TBL] [Abstract][Full Text] [Related]
16. Approaches to Improve Chemically Defined Synthetic Peptide Vaccines.
Hos BJ; Tondini E; van Kasteren SI; Ossendorp F
Front Immunol; 2018; 9():884. PubMed ID: 29755468
[TBL] [Abstract][Full Text] [Related]
17. Peptide-based vaccines for cancer therapy.
Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
[TBL] [Abstract][Full Text] [Related]
18. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM
J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034
[TBL] [Abstract][Full Text] [Related]
19. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
20. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
Front Immunol; 2019; 10():1939. PubMed ID: 31475002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]